BeOne Medicines AG (BEIGF)
OTCMKTS · Delayed Price · Currency is USD
24.92
0.00 (0.00%)
At close: Nov 10, 2025
BeOne Medicines AG Revenue
In the year 2025, BeOne Medicines AG had annual revenue of $5.34B with 40.23% growth. BeOne Medicines AG had revenue of $1.50B in the quarter ending December 31, 2025, with 32.84% growth.
Revenue
5.34B
Revenue Growth
+40.23%
P/S Ratio
6.58
Revenue / Employee
485.73K
Employees
11,000
Market Cap
35.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.34B | 1.53B | 40.23% |
| Dec 31, 2024 | 3.81B | 1.35B | 54.96% |
| Dec 31, 2023 | 2.46B | 1.04B | 73.65% |
| Dec 31, 2022 | 1.42B | 239.64M | 20.37% |
| Dec 31, 2021 | 1.18B | 867.41M | 280.83% |
| Dec 31, 2020 | 308.87M | -119.34M | -27.87% |
| Dec 31, 2019 | 428.21M | 229.99M | 116.03% |
| Dec 31, 2018 | 198.22M | -40.17M | -16.85% |
| Dec 31, 2017 | 238.39M | 237.32M | 22,179.16% |
| Dec 31, 2016 | 1.07M | -7.75M | -87.86% |
| Dec 31, 2015 | 8.82M | -4.22M | -32.37% |
| Dec 31, 2014 | 13.04M | 1.89M | 16.93% |
| Dec 31, 2013 | 11.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
BeOne Medicines AG News
- 2 days ago - BeiGene Non-GAAP EPS of $1.95 beats by $0.65, revenue of $1.5B beats by $50M - Seeking Alpha
- 3 days ago - BeiGene (ONC) Q4 Earnings Preview: Revenue Set for Growth - GuruFocus
- 3 days ago - BeiGene Q4 2025 Earnings Preview - Seeking Alpha
- 10 months ago - U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene - Business Wire
- 11 months ago - BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer - Business Wire